



Prevena™
Incision Therapy

PROMISES study data suggests 3M™ Prevena™ Therapy can help advance the standard of care

Promising new data from a randomized controlled trial further affirms that Prevena Therapy significantly reduces the risk of 90-day surgical site complications (SSCs) and postop readmissions.



The PROMISES (Post-market, Randomized, Open-Label, Multicenter Study to evaluate Effectiveness) Trial

The Effectiveness of Closed Incision Negative Pressure Therapy versus Silver-Impregnated Dressings in Mitigating Surgical Site Complications in High-Risk Patients After Revision Knee Arthroplasty.

Higuera-Rueda CA, Emara AK, Nieves-Malloure Y, Klika AK, Cooper HJ, Cross MB, Guild GN, Nam D, Nett MP, Scuderi GR, Cushner FD, Piuze NS, Silverman RP. J. Arthroplasty 2021; doi: 10.1016/j.arth.2021.02.076

Study Design

Post-market, randomized, open-label, multicenter study.

Study Purpose

- Evaluate the effectiveness of closed incision negative pressure therapy (ciNPT) versus standard of care (SOC) dressings in reducing surgical site complications (SSCs).

Methods

- A total of 294 revision total knee arthroplasty (rTKA) patients (15 centers) at high-risk for wound complications were randomized to ciNPT or SOC (n=146 each) and stratified by revision type (aseptic vs. septic). Demographics, comorbidities, causes of revision and duration of treatment were similar between cohorts ($p > 0.05$).
- 242 patients with incisions completed follow-up, including 124 patients treated with 3M™ Prevena™ Therapy (ciNPT) and 118 patients treated with an antimicrobial silver-impregnated dressing (SOC).
- Primary outcome was the 90-day incidence of SSCs with stratification in accordance with revision type. Secondary outcomes were the 90-day health care utilization parameters (readmission, reoperation, dressing changes, and visits) and patient-reported outcomes (PRO). Treatment-related adverse events were compared and stratified as severe and non-severe.

Results

- Compared to SOC, patients in the Prevena Therapy group demonstrated:
 - Significantly decreased rates of surgical site complications (ciNPT 3.4% vs. SOC 14.3%, $p = 0.0013^*$)
 - Significantly lower readmission rates (ciNPT 3.4% vs. SOC 10.2%, $p = 0.0208^*$)
 - Reduced dressing changes (ciNPT 1.1+0.29 vs. SOC 1.3 +0.96, $p = 0.0003^*$)

Conclusions

- Prevena Therapy significantly mitigated 90-day surgical site complications, readmission rates, and reduced frequency of dressing changes compared with the standard of care among high-risk rTKA patients.
 - Treatment-related adverse effects were similar between both cohorts.
 - The benefit of ciNPT on specific SSCs and post-rTKA patient-reported outcomes (PRO) was not established and further studies are warranted.

Patients treated with Prevena Therapy were:

4X* LESS LIKELY
to experience a post-operative
90-day surgical site complication

3X* LESS LIKELY
to be readmitted compared to
the standard of care group

*Calculation(s) are derived based on relative patient group incidence rate reported in this study. *Statistically significant ($p < 0.05$)



3M Company

2510 Conway Ave.
St. Paul, MN 55144 USA

Phone 1-800-275-4524 (NPWT products)

1-800-228-3957

Web 3M.com/Medical

NOTE: Specific indications, limitations, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.

© 2021 3M. All rights reserved. 3M and the other marks shown are marks and/or registered marks. Unauthorized use prohibited. PRA-PM-US-03119 (04/21)